Gender differences in breast cancer

Analysis of 13,000 breast cancers in men from the national cancer data base

Jon M. Greif, Christopher M. Pezzi, Vicki Klimberg, Lisa Bailey, Marlene Zuraek

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose. To examine gender-specific differences in breast cancer utilizing the National Cancer Data Base (NCDB). Methods. Breast cancer patients entered in the NCDB from 1998 through 2007 were compared by gender for demographics, tumor characteristics, treatment, and outcomes. Results. A total of 13,457 men were compared to 1,439,866 women. Men were older, more often African American, less often Hispanic, had larger tumors, less often had low-grade disease, less often had stage 0 or I disease, and were more likely to have metastases to lymph nodes and/or distantly. Cancers in men were less likely lobular and more likely estrogen receptor and/or progesterone receptor positive. Men were more likely to have total mastectomy and less likely to receive radiotherapy. There was no difference in chemotherapy and little difference in hormone therapy rates. Differences in overall survival (OS) were highly significant (p<0.0001): 83 % 5-year OS for women with breast cancer (median survival 129 months) versus 74 % for men (median survival 101 months). Women had better 5-year OS (p<0.0001) for stage 0 (94 vs. 90 %), stage I (90 vs. 87 %), and stage II (82 vs. 74 %) breast cancer. There were no differences in 5-year OS for stage III (56.9 vs. 56.5 %, p = 0.99) or stage IV (19 vs. 16 %, p = 0.20) disease. Conclusions. At first glance, this large study demonstrated numerous gender-specific differences. However, after accounting for differences in presentation, absence of data on disease-specific survival, and inherent deficiencies in reporting cancer registry data, breast cancer in men and women appears more alike than different.

Original languageEnglish (US)
Pages (from-to)3199-3204
Number of pages6
JournalAnnals of Surgical Oncology
Volume19
Issue number10
DOIs
StatePublished - Oct 2012
Externally publishedYes

Fingerprint

Databases
Breast Neoplasms
Survival
Neoplasms
Simple Mastectomy
Progesterone Receptors
Hispanic Americans
Estrogen Receptors
African Americans
Registries
Radiotherapy
Lymph Nodes
Demography
Hormones
Neoplasm Metastasis
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Gender differences in breast cancer : Analysis of 13,000 breast cancers in men from the national cancer data base. / Greif, Jon M.; Pezzi, Christopher M.; Klimberg, Vicki; Bailey, Lisa; Zuraek, Marlene.

In: Annals of Surgical Oncology, Vol. 19, No. 10, 10.2012, p. 3199-3204.

Research output: Contribution to journalArticle

Greif, Jon M. ; Pezzi, Christopher M. ; Klimberg, Vicki ; Bailey, Lisa ; Zuraek, Marlene. / Gender differences in breast cancer : Analysis of 13,000 breast cancers in men from the national cancer data base. In: Annals of Surgical Oncology. 2012 ; Vol. 19, No. 10. pp. 3199-3204.
@article{4867bf27501e421885f13c22f50baa14,
title = "Gender differences in breast cancer: Analysis of 13,000 breast cancers in men from the national cancer data base",
abstract = "Purpose. To examine gender-specific differences in breast cancer utilizing the National Cancer Data Base (NCDB). Methods. Breast cancer patients entered in the NCDB from 1998 through 2007 were compared by gender for demographics, tumor characteristics, treatment, and outcomes. Results. A total of 13,457 men were compared to 1,439,866 women. Men were older, more often African American, less often Hispanic, had larger tumors, less often had low-grade disease, less often had stage 0 or I disease, and were more likely to have metastases to lymph nodes and/or distantly. Cancers in men were less likely lobular and more likely estrogen receptor and/or progesterone receptor positive. Men were more likely to have total mastectomy and less likely to receive radiotherapy. There was no difference in chemotherapy and little difference in hormone therapy rates. Differences in overall survival (OS) were highly significant (p<0.0001): 83 {\%} 5-year OS for women with breast cancer (median survival 129 months) versus 74 {\%} for men (median survival 101 months). Women had better 5-year OS (p<0.0001) for stage 0 (94 vs. 90 {\%}), stage I (90 vs. 87 {\%}), and stage II (82 vs. 74 {\%}) breast cancer. There were no differences in 5-year OS for stage III (56.9 vs. 56.5 {\%}, p = 0.99) or stage IV (19 vs. 16 {\%}, p = 0.20) disease. Conclusions. At first glance, this large study demonstrated numerous gender-specific differences. However, after accounting for differences in presentation, absence of data on disease-specific survival, and inherent deficiencies in reporting cancer registry data, breast cancer in men and women appears more alike than different.",
author = "Greif, {Jon M.} and Pezzi, {Christopher M.} and Vicki Klimberg and Lisa Bailey and Marlene Zuraek",
year = "2012",
month = "10",
doi = "10.1245/s10434-012-2479-z",
language = "English (US)",
volume = "19",
pages = "3199--3204",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Gender differences in breast cancer

T2 - Analysis of 13,000 breast cancers in men from the national cancer data base

AU - Greif, Jon M.

AU - Pezzi, Christopher M.

AU - Klimberg, Vicki

AU - Bailey, Lisa

AU - Zuraek, Marlene

PY - 2012/10

Y1 - 2012/10

N2 - Purpose. To examine gender-specific differences in breast cancer utilizing the National Cancer Data Base (NCDB). Methods. Breast cancer patients entered in the NCDB from 1998 through 2007 were compared by gender for demographics, tumor characteristics, treatment, and outcomes. Results. A total of 13,457 men were compared to 1,439,866 women. Men were older, more often African American, less often Hispanic, had larger tumors, less often had low-grade disease, less often had stage 0 or I disease, and were more likely to have metastases to lymph nodes and/or distantly. Cancers in men were less likely lobular and more likely estrogen receptor and/or progesterone receptor positive. Men were more likely to have total mastectomy and less likely to receive radiotherapy. There was no difference in chemotherapy and little difference in hormone therapy rates. Differences in overall survival (OS) were highly significant (p<0.0001): 83 % 5-year OS for women with breast cancer (median survival 129 months) versus 74 % for men (median survival 101 months). Women had better 5-year OS (p<0.0001) for stage 0 (94 vs. 90 %), stage I (90 vs. 87 %), and stage II (82 vs. 74 %) breast cancer. There were no differences in 5-year OS for stage III (56.9 vs. 56.5 %, p = 0.99) or stage IV (19 vs. 16 %, p = 0.20) disease. Conclusions. At first glance, this large study demonstrated numerous gender-specific differences. However, after accounting for differences in presentation, absence of data on disease-specific survival, and inherent deficiencies in reporting cancer registry data, breast cancer in men and women appears more alike than different.

AB - Purpose. To examine gender-specific differences in breast cancer utilizing the National Cancer Data Base (NCDB). Methods. Breast cancer patients entered in the NCDB from 1998 through 2007 were compared by gender for demographics, tumor characteristics, treatment, and outcomes. Results. A total of 13,457 men were compared to 1,439,866 women. Men were older, more often African American, less often Hispanic, had larger tumors, less often had low-grade disease, less often had stage 0 or I disease, and were more likely to have metastases to lymph nodes and/or distantly. Cancers in men were less likely lobular and more likely estrogen receptor and/or progesterone receptor positive. Men were more likely to have total mastectomy and less likely to receive radiotherapy. There was no difference in chemotherapy and little difference in hormone therapy rates. Differences in overall survival (OS) were highly significant (p<0.0001): 83 % 5-year OS for women with breast cancer (median survival 129 months) versus 74 % for men (median survival 101 months). Women had better 5-year OS (p<0.0001) for stage 0 (94 vs. 90 %), stage I (90 vs. 87 %), and stage II (82 vs. 74 %) breast cancer. There were no differences in 5-year OS for stage III (56.9 vs. 56.5 %, p = 0.99) or stage IV (19 vs. 16 %, p = 0.20) disease. Conclusions. At first glance, this large study demonstrated numerous gender-specific differences. However, after accounting for differences in presentation, absence of data on disease-specific survival, and inherent deficiencies in reporting cancer registry data, breast cancer in men and women appears more alike than different.

UR - http://www.scopus.com/inward/record.url?scp=84868192070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868192070&partnerID=8YFLogxK

U2 - 10.1245/s10434-012-2479-z

DO - 10.1245/s10434-012-2479-z

M3 - Article

VL - 19

SP - 3199

EP - 3204

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 10

ER -